Merck KGaA Strengthens Synthetic Lethality Pipeline with US$6.9 B Artios Alliance

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 12 (Table of Contents)

Published: 10 Dec-2020

DOI: 10.3833/pdr.v2020.i12.2577     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its oncology portfolio, Merck KGaA has entered into a three-year collaboration with Artios Pharma to discover and develop precision oncology candidates for up to eight targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details